7 powodów, dla których warto stosować donepezil razem z memantyną Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2016
Słowa kluczowe:
choroba Alzheimera, leczenie objawowe, donepezil, memantyna
##plugins.themes.bootstrap3.article.main##
Abstrakt
Choroba Alzheimera jest przewlekłą chorobą ośrodkowego układu nerwowego o nie do końca poznanym mechanizmie. Z uwagi na brak leczenia przyczynowego wysiłki terapeutyczne koncentrują się na udoskonaleniu leczenia objawowego. Na rynku obecne są cztery leki prokognitywne: donepezil, riwastygmina, galantamina, memantyna, wpływające na dwa główne układy neuroprzekaźnictwa – cholinergiczny i glutamatergiczny. Stwierdzono efektywność i bezpieczeństwo leczenia łączonego donepezilem i memantyną, które wpływa korzystnie na funkcje poznawcze, objawy psychopatologiczne i zaburzenia zachowania.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Parnowski , T. (2016). 7 powodów, dla których warto stosować donepezil razem z memantyną . Medycyna Faktów , 9(2(31), 140-145. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2252
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Morris J.C., Roe C.M., Grant E.A. et al.: Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 2009; 66(12): 1469-1475.
2. Francis P.T., Palmer A.M., Snape M. et al.: The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999; 66: 137-147.
3. Danysz W., Parsons C.G., Möbius H.J. et al.: Neuroprotective and symptomatological Action of memantine relevant for Alzheimer’s disease – a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Research 1999; 2: 85-97.
4. Cummings J.L., Isaacson A., Schmitt F.A., Velting D.M.: Practical algorithm for managing Alzheimer’s disease: what, when, and why? Ann. Clin. Transl. Neurol. 2015; 2(3): 307-323.
5. Cummings J.L., McRae T., Zhang R.: Donepezil – Sertraline Study Group. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am. J. Geriatr. Psychiatry 2006; 14(7): 605-612.
6. Suzuki H., Inoue Y., Mikami K., Gen K.: The influence and changes in the dosages of concomitantly used psychotropic drugs associated with the discontinuation of donepezil in severe Alzheimer’s disease with behavioral and psychological symptoms on dementia: a preliminary open-label trial. Ther. Adv. Psychopharmacol. 2014; 4(1): 37-42.
7. Wilkinson D., Schindler R., Schwam E. et al.: Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2009; 28(3): 244-251.
8. Birks J.: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev. 2006; 25(1): CD005593. Review.
9. Gauthier S., Wirth Y., Möbius H.J.: Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry 2005; 20(5): 459-464.
10. Cheewakriengkrai L., Gauthier S.A.: 10-year perspective on donepezil. Expert Opin. Pharmacother. 2013; 14(3): 331-338.
11. Atri A., Shaughnessy L.W., Locascio J.J. et al.: Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2008; 22(3): 209-221.
12. Lopez O.L., Becker J.T., Wahed A.S.: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.J. Neurol. Neurosurg. Psychiatry 2009; 80(6): 600-607.
13. Atri A., Hendrix S.B., Pejović V. et al.: Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers. Res. Ther. 2015; 7(1): 28.
14. Matsuzono K., Hishikawa N., Ohta Y. et al.: Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study. J. Alzheimers Dis. 2015; 45(3): 771-780.
15. Howard R., McShane R., Lindesay J. et al.: Donepezil and memantine for moderate to severe Alzheimer’s disease. NEJM 2012; 366(10): 893-903.
16. Rungsanpanya T., Muangpaisan W., Praditsuwan R.: Clinical practice with antidementia drugs in a geriatric clinic. J. Med. Assoc. Thai. 2012; 95(8): 1081-1089.
17. Pariente A., Sanctussy D.J., Miremont-Salamé G. et al.: l’Association Française des Centres Régionaux de Pharmacovigilance (CRPV). Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting. CNS Drugs. 2010; 24(1): 55-63.
18. European Medicines Evaluation Agency Ebixa EPAR Scientific Discussion EMEA 2006 [online].
19. Babai S., Auriche P., Le- Louët H.: Comparison of adverse drug reactions with donepezil versus memantine: analysis of the French Pharmacovigilance Database. Therapie 2010; 65(3): 255-259.
20. Jones R.W.: A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int. J. Geriatr. Psychiatry 2010; 25(6): 547-553.
21. Akasofu S., Kimura M., Kosasa T. et al.: Study of neuroprotection of donepezil, a therapy for Alzheimer’s disease. Chem. Biol. Interact. 2008; 175(1-3): 222-226.
22. Castaneda M.T., Lopez E.D., Touhami A. et al.: Neuroprotection of medial septal cholinergic neurons by memantine after intralateral septal injection of Aβ1-40. Neuroreport. 2015; 26(8): 450-454.
23. Malouf R., Birks J.: Donepezil for vascular cognitive impairment. Cochrane Database Syst. Rev. 2004 (1): CD004395. Review.
24. Etsuro M., Manabu I., Reiko N. et al.:. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial. Alzheimer’s Research & Therapy 2015; 7: 5.
25. Aarsland D., Ballard C., Rongve A. et al.: Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Curr. Neurol. Neurosci. Rep. 2012; 12(5): 492-501.
26. Hort J., O’Brien J.T., Gainotti G et al.: EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur. J. Neurol. 2010; 17(10): 1236-1248.
2. Francis P.T., Palmer A.M., Snape M. et al.: The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999; 66: 137-147.
3. Danysz W., Parsons C.G., Möbius H.J. et al.: Neuroprotective and symptomatological Action of memantine relevant for Alzheimer’s disease – a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Research 1999; 2: 85-97.
4. Cummings J.L., Isaacson A., Schmitt F.A., Velting D.M.: Practical algorithm for managing Alzheimer’s disease: what, when, and why? Ann. Clin. Transl. Neurol. 2015; 2(3): 307-323.
5. Cummings J.L., McRae T., Zhang R.: Donepezil – Sertraline Study Group. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am. J. Geriatr. Psychiatry 2006; 14(7): 605-612.
6. Suzuki H., Inoue Y., Mikami K., Gen K.: The influence and changes in the dosages of concomitantly used psychotropic drugs associated with the discontinuation of donepezil in severe Alzheimer’s disease with behavioral and psychological symptoms on dementia: a preliminary open-label trial. Ther. Adv. Psychopharmacol. 2014; 4(1): 37-42.
7. Wilkinson D., Schindler R., Schwam E. et al.: Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2009; 28(3): 244-251.
8. Birks J.: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev. 2006; 25(1): CD005593. Review.
9. Gauthier S., Wirth Y., Möbius H.J.: Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry 2005; 20(5): 459-464.
10. Cheewakriengkrai L., Gauthier S.A.: 10-year perspective on donepezil. Expert Opin. Pharmacother. 2013; 14(3): 331-338.
11. Atri A., Shaughnessy L.W., Locascio J.J. et al.: Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2008; 22(3): 209-221.
12. Lopez O.L., Becker J.T., Wahed A.S.: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.J. Neurol. Neurosurg. Psychiatry 2009; 80(6): 600-607.
13. Atri A., Hendrix S.B., Pejović V. et al.: Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers. Res. Ther. 2015; 7(1): 28.
14. Matsuzono K., Hishikawa N., Ohta Y. et al.: Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study. J. Alzheimers Dis. 2015; 45(3): 771-780.
15. Howard R., McShane R., Lindesay J. et al.: Donepezil and memantine for moderate to severe Alzheimer’s disease. NEJM 2012; 366(10): 893-903.
16. Rungsanpanya T., Muangpaisan W., Praditsuwan R.: Clinical practice with antidementia drugs in a geriatric clinic. J. Med. Assoc. Thai. 2012; 95(8): 1081-1089.
17. Pariente A., Sanctussy D.J., Miremont-Salamé G. et al.: l’Association Française des Centres Régionaux de Pharmacovigilance (CRPV). Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting. CNS Drugs. 2010; 24(1): 55-63.
18. European Medicines Evaluation Agency Ebixa EPAR Scientific Discussion EMEA 2006 [online].
19. Babai S., Auriche P., Le- Louët H.: Comparison of adverse drug reactions with donepezil versus memantine: analysis of the French Pharmacovigilance Database. Therapie 2010; 65(3): 255-259.
20. Jones R.W.: A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int. J. Geriatr. Psychiatry 2010; 25(6): 547-553.
21. Akasofu S., Kimura M., Kosasa T. et al.: Study of neuroprotection of donepezil, a therapy for Alzheimer’s disease. Chem. Biol. Interact. 2008; 175(1-3): 222-226.
22. Castaneda M.T., Lopez E.D., Touhami A. et al.: Neuroprotection of medial septal cholinergic neurons by memantine after intralateral septal injection of Aβ1-40. Neuroreport. 2015; 26(8): 450-454.
23. Malouf R., Birks J.: Donepezil for vascular cognitive impairment. Cochrane Database Syst. Rev. 2004 (1): CD004395. Review.
24. Etsuro M., Manabu I., Reiko N. et al.:. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial. Alzheimer’s Research & Therapy 2015; 7: 5.
25. Aarsland D., Ballard C., Rongve A. et al.: Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Curr. Neurol. Neurosci. Rep. 2012; 12(5): 492-501.
26. Hort J., O’Brien J.T., Gainotti G et al.: EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur. J. Neurol. 2010; 17(10): 1236-1248.